Richard W. Allen
Richard W. Allen (R-GA) bought $15K-$50K of $NFLX (Netflix, Inc. - Common Stock) on May 16, 2025, part of 3 transactions in this filing (2 buys, 1 sells).
HillSignal flagged 1 timing concern on this filing — trades that line up closely with related legislative or contract activity.
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Suspicious Timing Detected
1 flagThese flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $NFLX | Netflix, Inc. - Common Stock | $15K-$50K | $119.15 | — | — | May 16, 2025 |
| BUY | Government Securities | US Treasury Bill 912797MS3 DUE 10/02/25(Government Securities) | $1K-$15K | — | — | — | May 16, 2025 |
| SELL | $TMO | Thermo Fisher Scientific Inc Common Stock | $15K-$50K | $412.06 | — | — | May 16, 2025 |
Connected Legislative Activity
7 signalsThese bills and contracts share tickers or sectors with this filing's trades.
RESULTS Act
The RESULTS Act (HR5269) is an early-stage bill aiming to stabilize Medicare reimbursement for clinical diagnostic lab tests by improving data accuracy. It has 77 cosponsors and a companion bill in the Senate but remains in committee with no near-term market impact. Real market data shows LH at $259 and DGX at $190.19, both down ~3% over 30 days, reflecting sector headwinds unrelated to this procedural legislation.
DeOndra Dixon INCLUDE Project Act of 2025
HR3491 (DeOndra Dixon INCLUDE Project Act) authorizes a Down syndrome research program at NIH but appropriates zero funding. With only 5 procedural actions over a year and stalled committee markup, the bill has no near-term market impact. No public companies are directly affected.
Lowering Broadband Costs for Consumers Act of 2025
HR4032 (Lowering Broadband Costs for Consumers Act) is an early-stage bill that would expand USF contribution requirements to broadband and edge providers. It remains in committee with no floor action, making near-term market impact negligible. If passed, $CMCSA, $T, $VZ, $GOOGL, $META, $AMZN, and $NFLX would face new recurring costs reducing segment margins by an estimated 1-3%.
Ellie’s Law
Ellie's Law (HR2678) is an early-stage authorization bill directing NINDS to research unruptured intracranial aneurysms. It authorizes zero dollars, has no funding appropriation, and has only been referred to committee. Market impact is negligible in the near term for device and research tool providers like MDT, TMO, ILMN, and DGX, as no actual spending exists and the legislative path is years from completion.
BRAIN Act
The BRAIN Act (HR2767) is an early-stage bill in the 119th Congress that authorizes no funding and has been referred to committee. Near-term market impact is negligible. The bill creates programmatic structures for brain tumor research, biospecimen transparency, and biomarker testing awareness, but actual market effects require future appropriations and bill text clarity. No publicly traded companies face material revenue exposure at this stage.
Reducing Hereditary Cancer Act
The Reducing Hereditary Cancer Act (HR4752) mandates Medicare coverage for germline mutation testing—a direct expansion of the addressable market for genetic diagnostics companies. The bill is in early committee stage (referred to Energy & Commerce and Ways & Means), with a Senate companion bill (S2760) also introduced. Real market data shows genetic testing/ diagnostics tickers have declined 0.09% to 5.12% in the past week, but this bill represents structural demand expansion independent of recent price action.
SEPSIS Act
The SEPSIS Act (S.1929) is an early-stage authorization bill that would create federal programs for sepsis research, education, and data collection. It authorizes but does not appropriate funding, and with only 6 cosponsors and referral to committee in June 2025, passage remains uncertain. Real market data shows all four diagnostic/lab stocks have declined 1-6% in the past week and 2-10% over 30 days, reflecting broader market pressure on healthcare despite the legislative catalyst.
Other Filings by Richard W. Allen
Free — no credit card
Get the next Allen trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.